title: Role for proton beam irradiation in treatment of pediatric CNS malignancies.
abstract: The ability to vary the proton energy (depth of beam penetration) and modulate the dose distribution at the end of range permits delivery of an increased dose to the designated cancer-containing volume with a reduced dose to overlying normal brain tissue. The evolution of childhood CNS malignancy following therapy is reviewed to identify radiation response variables indicating where the proton dose distribution will improve the therapeutic ratio. The review documents that of the 1262 children expected to develop CNS malignancy in 1989, only 43% will survive 5 years. About 75% of those with medulloblastoma and over 90% with astrocytoma die from persistent (in-field) disease. When the patient has been treated with radiation, it is accepted that disease persistence indicates the cancer dose was insufficient. Potentially 536 children could show an improved incidence of local control and improved survival from an increased cancer dose available from proton irradiation. As the total dose and volume of brain irradiated is increased about 1800 cGy, brain dysfunction increases, producing a spectrum of functional and intellectual deficits which are age and volume related. About 900 irradiated patients would have fewer in-field histologic and functional changes if the dose to normal brain, or the volume of brain irradiated, is reduced by an improved dose distribution. A proton beam treatment plan, delivering a cancer dose of 7400 cGy, is simulated for a thalamic astrocytoma. The dose distribution of this plan is compared with an x-ray plan used to treat a patient, in which a dose of 5400 cGy was delivered to the astrocytoma. Comparative isodose distributions and dose-volume histograms indicate a decreased integral dose to normal brain and a decreased volume of normal brain irradiated, even as the cancer dose is boosted 2000 cGy with protons.
authors.affiliation: Department of Radiation Medicine, Loma Linda University Medical Center, CA 92354.
authors.forename: J O
authors.initials: JO
authors.lastname: Archambeau
authors.forename: J D
authors.initials: JD
authors.lastname: Slater
authors.forename: J M
authors.initials: JM
authors.lastname: Slater
authors.forename: R
authors.initials: R
authors.lastname: Tangeman
mesh_terms: D001932:Brain Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*; D002648:Child; D006801:Humans; D015201:Meta-Analysis as Topic; D011379:Prognosis; D011522:Protons; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D014481:United States / Q000453:epidemiology
chemical_list: D011522:Protons